**Core Concept**
Metformin is an oral antidiabetic drug used in the treatment of type 2 diabetes mellitus. Its mechanism of action involves the inhibition of hepatic gluconeogenesis, which is the process of glucose production in the liver.

**Why the Correct Answer is Right**
Metformin acts by inhibiting the mitochondrial respiratory chain complex I, which leads to a decrease in the production of ATP (adenosine triphosphate) in the liver. This results in a decrease in the activity of the enzyme glyceraldehyde-3-phosphate dehydrogenase, which is involved in the gluconeogenic pathway. By inhibiting this enzyme, metformin reduces the production of glucose in the liver, thereby decreasing blood glucose levels. Additionally, metformin also increases the sensitivity of peripheral tissues to insulin by activating the AMP-activated protein kinase (AMPK) pathway.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not accurately describe the mechanism of action of metformin. Metformin does not work by stimulating insulin release from the pancreas.
**Option B:** This option is incorrect because it refers to the mechanism of action of sulfonylureas, not metformin. Sulfonylureas work by stimulating insulin release from the pancreas.
**Option C:** This option is incorrect because it refers to the mechanism of action of thiazolidinediones, not metformin. Thiazolidinediones work by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), which increases insulin sensitivity.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that metformin is a first-line treatment for type 2 diabetes mellitus due to its efficacy and safety profile. It is also worth noting that metformin can cause lactic acidosis, a rare but potentially life-threatening side effect, especially in patients with renal impairment.

**Correct Answer: D. Inhibition of mitochondrial respiratory chain complex I and activation of AMP-activated protein kinase (AMPK) pathway.**